Skip to main content

beruzatatug pelitecan

Generic: Beruzatatug Pelitecan

beruzatatug pelitecan: 2 clinical trials tracked.

beruzatatug pelitecan evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about beruzatatug pelitecan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trials (2)

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520·Phase 1/Phase 2·BNTX
Recruiting

Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participant

InterventionalRandomizedopen880 targetStarted 2025-09Completion 2030-0650 sites · Australia, China, Germany, Italy…BioNTech SE

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

NCT07070232·Phase 1/Phase 2·BNTX
Recruiting

Primary endpoint: Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)

InterventionalRandomizedopen1,438 targetStarted 2025-08Completion 2030-0350 sites · Australia, Belgium, Germany, Italy…BioNTech SE